Notice NOT-DK-17-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-18-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit applications proposing research that can lead to advancements in the understanding of elder mistreatment (emotional abuse, physical abuse, and sexual abuse; financial exploitation; abandonment; and neglect) and lay the foundation for the future design of mechanistically focused interventions for individuals at risk for mistreating elders, for promoting recovery and resilience in the maltreated and their families, and for preventing re-perpetration for those who have inflicted harm. Applications are solicited from multidisciplinary teams which include researchers from the fields of elder mistreatment, child abuse and neglect, intimate partner violence, and/or emergency medicine to pursue research in two priority areas: (1) the development of new and innovative tools and methods for the screening and detection of elder mistreatment; and (2) the identification of modifiable risk factors for elder mistreatment and modifiable protective factors, with potential to prevent maltreatment and/or enable individuals who have been mistreated and those who have mistreated others to overcome adversity and thrive. All applications should propose evidence-based strategies for addressing ethical challenges surrounding informed consent and study design in the research proposed, and to employ, when possible, best practices established in the fields of child abuse and neglect and/or intimate partner violence.

Funding Opportunity PA-17-286 from the NIH Guide for Grants and Contracts. The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.

Funding Opportunity RFA-FD-17-012 from the NIH Guide for Grants and Contracts. The Food and Drug Administration's (FDA), Office of Regulatory Affairs (ORA), Office of Resource Management (ORM), Division of Human Resource Development (DHRD) is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement Grant. The goals of this Cooperative Agreement Grant are to continue the development of the Integrated Food Safety System (IFSS) National Curriculum Standard (NCS) for the laboratory competency and curriculum frameworks, further work on the development and validation of competency statements, and create, develop and deliver courses to IFSS laboratorians nationwide. Under FSMA Section 209, FDA is directed to improve the training of state, local, territorial and tribal food safety officials and set standards and administer training and education programs to ensure a competent work force doing comparable work.

Notice NOT-RM-17-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-18-008 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage research projects that investigate covalent RNA modifications in HIV/AIDS and substance use disorders. Identifying modifications involved in HIV function as well as understanding the mechanisms involved and how these processes interact with chronic drug exposure could lay the foundation for the development of future novel therapeutics to treat HIV in patients with SUDs.

Funding Opportunity RFA-DA-18-009 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage research projects that investigate covalent RNA modifications in HIV/AIDS and substance use disorders. Identifying modifications involved in HIV function as well as understanding the mechanisms involved and how these processes interact with chronic drug exposure could lay the foundation for the development of future novel therapeutics to treat HIV in patients with SUDs.

Notice NOT-MH-17-030 from the NIH Guide for Grants and Contracts

Notice NOT-MH-17-029 from the NIH Guide for Grants and Contracts

Notice NOT-AA-17-004 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-058 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-060 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-061 from the NIH Guide for Grants and Contracts

Notice NOT-CA-17-059 from the NIH Guide for Grants and Contracts

Notice NOT-AT-17-010 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-065 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-024 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-023 from the NIH Guide for Grants and Contracts

Notice NOT-NR-17-021 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-276 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NIH StrokeNet centers and potential new stroke centers to participate as a Regional Coordinating Stroke Center in the NIH StrokeNet clinical trials network. The goal of this existing network is to maximize efficiencies to develop, promote and conduct high-quality, multi-site clinical trials focused on key interventions in stroke prevention, treatment, and recovery with the objective to have a balanced portfolio between all three approaches. Exploratory Phase 1/2 and confirmatory Phase 3 clinical trials as well as biomarker-validation studies that are immediately preparatory to trials will be coordinated through separate National Clinical Coordinating (NCC) and National Data Management Centers (NDMC).